Importantly, both selpercatinib and pralsetinib efficacy appears independent of the mechanism by which RET is activated – response rates have been similar in cancers containing RET M918T, other missense RET variants associated with MEN2A and RET fusions, emphasizing the central role RET kinase activity plays in these cancers. The gene discussed is RET; the disease is cancer.